Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6371-6390

  Allison, Brett D ^a   Phuong, Victor K ^a   McAtee, Laura C ^a   Rosen, Mark ^a   Morton, Magda ^a   Prendergas, Clodagh ^a,b   Barrett, Terry ^a   Lagaud, Guy ^a   Freedman, Jamie ^a   Li, Na ^a   Wu, Xiaodong ^a   Venkatesan, Hariharan ^a   Pippel, Marna ^a   Woods, Craig ^a   Rizzolio, Michèle C ^a   Hack, Michael ^a   Hoey, Kenway ^a   Deng, Xiaohu ^a   King, Christopher ^a   Shankley, Nigel P ^a   Rabinowitz, Michael H ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [(2,1,3 BENZOTHIADIAZOL 4 YLSULFONYL)AMINO] 4 BROMOBENZOYL]PIPERIDINE; 1 [2 [(2,1,3 BENZOTHIADIAZOL 4 YLSULFONYL)AMINO] 5 CHLOROBENZOYL]PIPERIDINE; 4 [4 IODO 2 [(5 QUINOXALINYLSULFONYL)AMINO]BENZOYL]MORPHOLINE; ANTHRANILIC ACID DERIVATIVE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; RADIOLIGAND; SULFONAMIDE; UNCLASSIFIED DRUG;

ACID SECRETION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EVALUATION; GALLBLADDER; GUINEA PIG; HIGH THROUGHPUT SCREENING; HUMAN; MALE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOASSAY; RAT; STOMACH MUSCLE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTHRANILIC ACIDS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; DOGS; DRUG STABILITY; GALLBLADDER; GASTRIC ACID; GUINEA PIGS; HUMANS; MALE; MICROSOMES, LIVER; MORPHOLINES; MUSCLE CONTRACTION; MUSCLE, SMOOTH; QUINOXALINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; STEREOISOMERISM; STOMACH; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33750125268     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060590x     Document Type: Article

References (44)

1. Reubi, J. C.; Schaer, J. C.; Waser, B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997, 57, 1377-1386.
2. Konturek, P. C.; Nikiforuk, A.; Kania, J.; Raithel, M.; Hahn, E. G.; Muhldorfer, S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2. PPARgamma and growth factors. Dig. Dis. Sci. 2004, 49, 1075-1083.
3. Colucci, R.; Blandizzi, C.; Tanini, M.; Vassalle, C.; Breschi, M. C.; Del Tacca, M. Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. Br. J. Pharmacol. 2005, 144, 338-348.
4. Durrant, L. G.; Spendlove, I. Cancer vaccines entering Phase III clinical trials. Expert Opin. Emerging Drugs 2003, 8, 489-500.
5. Watson, S. A.; Gilliam, A. D. G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin. Biol. Ther. 2001, 1, 309-317.
6. Vakil, N. Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2004, 19, 1041-1049.
7. Lehmann, F.; Hildebrand, P.; Beglinger, C. New molecular targets for treatment of peptic ulcer disease. Drugs 2003, 63, 1785-1797.
8. Gillen, D.; McColl, K. E. Problems related to acid rebound and tachyphylaxis. Best Pract. Res., Clin. Gastroenterol. 2001, 15, 487-495.
9. For a review see: Herranz, R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med. Res. Rev. 2003, 23, 559-605.
10. Lin, J. H.; Storey, D. E.; Chen, I. W.; Xu, X. Improved Oral Absorption of L-365.260, a Poorly Soluble Drug. Biopharm. Drug Dispos. 1996, 17, 1-15.
11. McDonald, I. M. CCK2 Receptor Antagonists. Exp. Opin. Ther. Pat. 2001, 11, 445-462.
12. Karaman, H.; Barton, R. J.; Robertson, B. E.; Lee, D. G. Preparation and Properties of Quaternary Ammonium and Phosphonium Permanganates. J. Org. Chem. 1984, 49, 4509-4516.
13. Bellamy, F. D.; Ou, K. Selective Reduction of Aromatic Nitro Compounds with Stannous Chloride in Nonacidic and Nonaqueous Medium. Tetrahedron Lett. 1984, 25, 839-842.
14. Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An Efficient Peptide Coupling Additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
15. Lin, H.-S.; Richett, M. E. Quinoxaline-5,8-Dione Derivatives, Their Preparation, and Their Use as Anticancer Agents. WO 9952365 A1, 1999.
16. Newman, M. S.; Karnes, H. A. Conversion of Phenols to Thiophenols Via Dialkylthiocarbamates. J. Org. Chem. 1966, 31, 3980-3984.
17. Kwart, H.; Evans, E. R. The Vapor Phase Rearrangement of Thionocarbonates and Thionocarbamates. J. Org. Chem. 1966, 31, 410-413.
18. Sakurai, H.; Ritonga, M. T. S.; Shibatani, H.; Hirao, T. Synthesis and Characterization of p-Phenylenediamine Derivatives Bearing an Electron-Acceptor Unit. J. Org. Chem. 2005, 70, 2754-2762.
19. Shankar, B. B.; Gilbert, E.; Rizvi, R. K.; Huang, C.; Kozlowski, J. A.; McCombie, S.; Shih, N.-Y. Preparation of Cannabinoid Receptor Ligands. WO 2006002133, 2006.
20. Ulrich, C. D.; Ferber, I.; Holicky, E.; Hadac, E.; Buell, G.; Miller, L. J. Molecular Cloning and Functional Expression of the Human Gallbladder Cholecystokinin A Receptor. Biochem. Biophys. Res. Commun. 1993, 193, 204-211.
21. Morton, M. F.; Pyati, J.; Dai, H.; Li, L.; Moreno, V.; Shankley, N. P. Molecular Cloning, Expression and Pharmacological Characterization of the Canine Cholecystokinin 1 Receptor. Br. J. Pharmacol. 2005, 145, 374-384.
22. Morton, M. F.; Liu, P. Q.; Reik, A.; de la Rosa, R.; Mendel, M.; Li, X. Y.; Case, C.; Pabo, C.; Moreno, V.; Pyati, J.; Shankley, N. P. Pharmacological Analysis of CCK2 Receptors Up-Regulated Using Engineered Transcription Factors. Regul. Pept. 2005, 129, 227-232.
23. Rabinowitz, M. H.; Masucci, J. Unpublished results.
24. Jaguar Quantum Mechanics, version 4.1; Ab initio density functional theory calculated using this application; Schrödinger, LLC: San Diego, CA.
25. Mulliken, R. S. Electronic Population Analysis on LCAO-MO Molecular-Wave Functions. IV. Bonding and Antibonding In LCAO and Valence-Bond Theories. J. Chem. Phys. 1955, 23, 2343-2346.
26. a automated computerized potentiometric system equipped with a pH electrode at 25 °C under argon gas (pION, Inc., Woburn. MA).
27. Rosen, M.; Allison, B.; Rabinowitz, M. H. Manuscript in preparation.
28. Low, C. M.; Buck, I. M.; Cooke, T.; Cushnir, J. R.; Kalindjian, S. B.; Kotecha, A.; Pether, M. J.; Shankley, N. P.; Vinter, J. G.; Wright, L. Scaffold Hopping With Molecular Field Points: Identification of a Cholecystokinin-2 (CCK2) Receptor Pharmacophore and its use in the Design of a Prototypical Series of Pyrrole- and Imidazole-Based CCK2 Antagonists. J. Med. Chem. 2005, 48, 6790-6802.
29. This intriguing result suggests that a tertiary amide group is required in this series to realize high receptor affinity. This is not necessarily the case, and the results of further studies in this area will be the subject of future disclosures from these laboratories.
30. Varnavas, A.; Valenta, V.; Berti, F.; Lassiani, L. Synthesis of N-Terminal Substituted Anthranilic Acid Dimer Derivatives for Evaluation on CCK Receptors. Farmaco 2001, 56, 555-564.
31. Varnavas, A.; Lassiani, L.; Valenta, V.; Berti, F.; Tontini, A.; Mennuni, L.; Makovec, F. Anthranilic Acid Based CCKI Antagonists: The 2-Indole Moiety May Represent a "Needle" According to the Recent Homonymous Concept. Eur. J. Med. Chem. 2004, 39, 85-97.
32. Varnavas, A.; Lassiani, L.; Valenta, V.; Berti, F.; Mennuni, L.; Makovec, F. Anthranilic Acid Derivatives: A New Class of Non-Peptide CCKI Receptor Antagonists. Bioorg. Med. Chem. 2003, 11, 741-751.
33. These studies will be the subjects of future publications from our laboratories.
34. Bishop, L. A.; Gerskowitch, V. P.; Hull, R. A.; Shankley, N. P.; Black, J. W. The Use of Receptor Desensitization to Analyse CCKA and CCKB/Gastrin Receptors Coupled to Contraction in Guinea-Pig Stomach Muscle. Br. J. Pharmacol. 1995, 114, 339-348.
35. Hultman, E. H. A Method for the Standardization of Cholecystokinin In Vitro. Acta Physiol. Scand. 1955, 33, 291-295.
36. Ghosh, M. N.; Schild, H. O. Continuous Recording of Acid Gastric Secretion in the Rat. Br. J. Pharmacol. Chemother. 1958, 13, 54-61.
37. Pare, W. P.; Isom, K. E.; Vincent, G. P., Jr.; Glavin, G. B. Preparation of a Chronic Gastric Fistula in the Rat. Lab Anim. Sci. 1977, 27, 244-247.
38. Brodie, D. A. Neurogenic Factors in Experimental Peptic Ulceration; McGill-Queens University Press: Montreal, 1963; pp 403-411.
39. Pesin, V. G.; Muravnik, R. S. Studies on 2,1,3-thia- and selenadiazole. XXXVI. Sulfonation and Oxidation. Latv. PSR Zinat. Akad. Vestis, Kim. Ser. 1965, 223-232.
40. Mikhailitsyn, F. S. Synthesis of 2,1,3-benzothiadiazole. I. New Sulfo Derivatives of 2,1,3-benzothiadiazole. Khim. Geterotsikl. Soedin. 1973, 19-21.
41. Bettoni, G.; Franchini, C.; Perrone, R.; Tortorella, V. Synthesis and Absolute Configuration of Substituted Morpholines. Tetrahedron 1980, 36, 409-415.
42. Enders, D.; Meyer. O.; Raabe, G.; Runsink, J. (S,S)-3,5-Dimethyl- morpholine, a Novel C2-Symmetric Auxiliary. First Application in [4+2]-cycloadditions Leading to 4-Oxohexahydropyridazine Derivatives. Synthesis 1994, 66-72.
43. Allison, B. D.; Hack, M. D.; Phuong, V. K.; Rabinowitz, M. H.; Rosen, M. D. Preparation of 5-[[(2-carbamoylphenyl)amino]sulfonyl]-quinoxaline compounds as cholecystokinin 2 modulators. U.S. Patent 2005038032, 20050217, 2005.
44. Cheng, Y.; Prusoff, W. H. Relationship Between the Inhibition Constant (Kl) and the Concentration of Inhibitorn Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.